14. Acute Lymphoblastic Leukemia

  1. Hussain I. Saba MD, PHD3 and
  2. Ghulam J. Mufti MB, DM, FRCP, FRCPATH4
  1. Susan O'Brien1,
  2. Stefan Faderl1,
  3. Deborah Thomas2 and
  4. Hagop M. Kantarjian1

Published Online: 24 MAR 2011

DOI: 10.1002/9781444394016.ch14

Advances in Malignant Hematology

Advances in Malignant Hematology

How to Cite

O'Brien, S., Faderl, S., Thomas, D. and Kantarjian, H. M. (2011) Acute Lymphoblastic Leukemia, in Advances in Malignant Hematology (eds H. I. Saba and G. J. Mufti), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444394016.ch14

Editor Information

  1. 3

    James A. Haley Veterans' Hospital, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, FL, USA

  2. 4

    Department of Haematological Medicine, Guy's and St Thomas' School of Medicine, King's College Hospital, London, UK

Author Information

  1. 1

    Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

  2. 2

    University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

Publication History

  1. Published Online: 24 MAR 2011
  2. Published Print: 16 APR 2011

ISBN Information

Print ISBN: 9781405196260

Online ISBN: 9781444394016



  • acute lymphoblastic leukemia;
  • ALL;
  • Philadelphia chromosome;
  • targeted therapy


Acute lymphoblastic leukemia (ALL) is characterized by a clonal expansion of hematopoietic blasts in the marrow, blood, and other organ systems. Although treatment of pediatric ALL has been a major success story, treatment of adults leads to outcomes that are inferior to those of children. ALL is increasingly recognized as a heterogeneous disease comprising many subsets for which different treatment strategies can be applied. Development of new drugs, molecular techniques for monitoring residual disease, and risk stratification, are creating new therapeutic paradigms in adult ALL therapy. Herein pertinent and recent literature on ALL biology and therapy are reviewed, as well as current strategies and potential implications of novel approaches to the management of adult ALL.